Clinical Integrative Research Center of Atlanta, Panda Neurology | Atlanta, GA

Research site

Location

5887 Glenridge Dr., Suite 140, Atlanta, Georgia, United States of America

Site insights

Top conditions

Top treatments

Soticlestat

ZX008

Cannabidiol

Fenfluramine Hydrochloride

Eslicarbazepine Acetate

Amitriptyline

334

Ubrogepant

Galcanezumab

AMG 334

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Cristy Miles

Verified by this site

Active trials

5 of 21 total trials

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine (REBUILD-1)

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Enrolling

Episodic Migraine

Drug: Galcanezumab

Drug: Placebo

A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not...

Enrolling

Migraine

Drug: Eptinezumab

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling

Attention-Deficit/Hyperactivity Disorder

Drug: Placebo

Drug: 100mg SPN-812

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17) (UBRO PEDS OLE)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only

Migraine

Drug: Ubrogepant

Locations recently updated

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) (Ubro Peds)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling

Migraine

Drug: Placebo-Matching Ubrogepant

Drug: Ubrogepant